No abstract available.
Fibromyalgia*

No abstract available.
Fibromyalgia*

No abstract available.
Fatigue Syndrome, Chronic* ; Fibromyalgia

Background: Fibromyalgia is a difficult-to-treat chronic musculoskeletal pain and tenderness syndrome. It is considered due to augmented pain processing in central nervous system. Interest in antiepileptic drugs, included pregabalin, for treatment of fibromyalgia is currently growing. This study aimed to investigate the effectiveness of pregabalin for fibromyalgia. Methods: We conducted the study according to the meta-analysis PRISMA guideline. Relevant randomized controlled trials (RCTs) were identified from a search of PubMed and Cochrane databases. Quality of selected studies was assessed using Jadad score for randomized placebo-controlled trials (RCT). Primary outcome was pain score reduction (30% and 50% reduction) and secondary outcome was patient global impression of change. Statistical analysis was performed using Review Manager 5.3. Results: Six international, multicenter, high-quality RCTs with 8-15 weeks duration of treatment met inclusion criteria. Four studies used different fixed dose (300 mg/d, 450 mg/d, 600mg/d) and 2 studies used titrated dose in evaluating the efficacy of pregabalin. There was statistically significant benefit of pregabalin over placebo in mean pain score reduction [odds ratio (OR) 1.81, 95% confidence interval (CI) 1.56-2.10 p < 0.00001 in fixed dose pregabalin 30% pain reduction; OR 2.06 95% CI 1.66-2.56 p < 0.00001 in fixed dose pregabalin 50% pain reduction; OR 1.53 95% CI 1.10-2.13 p 0.01 in titrated dose pregabalin 30% pain reduction; OR 1.80 95% CI 1.12-2.88 p 0.01 in titrated dose pregabalin 50% pain reduction]. Pregabalin also demonstrated significantly better patient global impression of change than placebo. No heterogeneity was seen in most groups. No publication bias was observed. Conclusion Our study showed pregabalin monotherapy was effective for pain treatment associated with fibromyalgia. Further studies with longer treatment duration are needed to confirm the long-term effectiveness of pregabalin for fibromyalgia treatment.
Fibromyalgia ; Pregabalin ; Meta-Analysis

We report on a case of severe generalized pain due to fibromyalgia syndrome, which was successfully treated with a variation of byakkoto. A 65-year-old Japanese woman had severe generalized pain which grew worse in warm environments, such as during the summer or when bathing. She also had pollakidipsia. We utilized a variation of byakkoto on the assumption that she was suffered from high inner heat. Her severe generalized pain resolved with this therapy. Although bushi-zai and saiko-zai are common prescriptions for fibromyalgia syndrome, byakkoto-variations may also be effective in cases where conditions are worsened by heat effect.
Fibromyalgia ; Pain ; Treated with ; Generalized aches and pains ; Syndrome

BACKGROUND: Dry eye is a disorder of the tear film caused by reduced tear production or excessive tear evaporation. A high incidence of sicca symptoms has been noted in fibromyalgia (FM) patients resulting in serious complications. This study was conducted to evaluate the incidence of dry eye by pathogenic mechanisms and to investigate the relationship between dry eye and symptom severity in FM patients. METHODS: Fifty patients that visited Maryknoll Hospital between March 2006 and December 2006 were included in the study. Enrolled patients underwent a Korean fibromyalgia impact questionnaire (KFIQ), ocular surface disease index (OSDI), Schirmer test and tear break up test (TBUT). The KFIQ and OSDI are used to assess the severity of fibromyalgia symptoms and dry eye symptoms, respectively. The Schirmer test and TBUT are used to assess reduced tear production and excessive tear evaporation, respectively. We assessed the OSDI, Schirmer test, TBUT, age and disease duration in terms of the KFIQ. RESULTS: The incidence of dry eye was high in FM patients (12.0% by the Schirmer test and 92.0% by the TBUT test). The OSDI positively correlated with the KFIQ (p=0.006). A positive correlation was observed between the Schirmer test and the KFIQ (p=0.024), but not between the TBUT and the KFIQ. CONCLUSIONS: In this study, dry eye was found to be common in FM patients. Excessive tear evaporation was a more common cause of dry eye than reduced tear production. The patients with more severe dry eye symptoms tend to have more severe FM symptoms.
Fibromyalgia* ; Humans ; Incidence ; Tears ; Surveys and Questionnaires

We demonstrated two patients with fibromyalgia syndrome (FMS), successfully treated with Kampo medicine, and considered the resemblance between the clinical manifestation of FMS and SHO for Kanzo-bushi-to.The first case was a 52-year-old women who consulted a local hospital in 2001 due to althralgia and myalgia in the left hand, bilateral elbows, shoulders and foot. Her condition was diagnosed as FMS without abnormal findings in the thorough medical examination. Treatment with NSAIDs was not effective, so she consulted our department in 2004. She was treated with Keishi-ni-eppi-itto-ka-ryojutsu-ka-boi-ogi-kakkon. After two mouths, her symptoms had reduced to 50% by visual analog scale (VAS). By March 2006, her symptoms had significantly decreased to 20% by VAS and NSAIDs became unnecessary.The second case was a 58-year-old woman who had suffered from tolerable pain in her right elbow for 10 years. In 2004, she visited the Department of Orthology at her local hospital due to pain in the neck, bilateral arms and shoulders. There were no findings on cervical X-ray or neurological examination, and NSAIDs were administered. Her symptoms did not resolve, therefore, she consulted our department in 2005. She was diagnosed with FMS, based on fulfilling the diagnostic criteria for FMS of ACR (American college of rheumatology) in 1990. She was treated with Kanzo-bushi-to. After 3 months, her symptoms had reduced to 30% by VAS. By Mar. 2006, her pain had redused to 25% by VAS and she was physically fit enough for a daily life.
CSF1-R ; symptoms <1> ; Medicine, Kampo ; Pain ; Fibromyalgia

OBJECTIVETo study the clinical features of juvenile primary fibromyalgia syndrome (FMS) and to evaluate outcome after treatment.

METHODSSix patients with juvenile primary FMS were registered in department of rheumatology and their clinical data were assessed, including degree of pain (visual analog scale, VAS), fatigue, depression, anxiety, sleep disturbances, arthrodynia, subjective joint swelling, abdominal pain, irritable bowel symptoms, urinary urgency, dysmenorrhea, morning stiffness, paresthesias, illness changes with weather, feeling worse with exercise, laboratory examination and outcome of treatment.

RESULTSAbdominal pain was the first symptom in 5 of the cases with juvenile primary FMS, diffuse aching and left knee pain were the first symptoms in one patient. All the 6 patients were misdiagnosed prior to their rheumatological evaluation. Diffuse aching, fatigue, sleep disturbances, illness changes with weather and feeling worse with exercise existed in all the 6 patients (100%), the mean pain score was 8.8 and the mean initial tender points (TP) count was 13.7. Arthrodynia, subjective joint swelling, abdominal pain, irritable bowel symptoms and urinary urgency existed in 5 of the 6 patients (83%). Dysmenorrhea existed in 4 (67%), depression in 3 (50%), morning stiffness in 2 (33%), paresthesias in 2 (33%) and anxiety in 2 (33%), respectively. The results of laboratory examination were normal and the outcomes of treatment were good.

CONCLUSIONJuvenile primary FMS may not be a rare disease and the clinicians should pay more attention to it for avoiding misdiagnosis.

Rheumatoid arthritis, fibromyalgia, and spondylarthritis are important diseases causing chronic pain and disability in rheumatologic areas. The classification and diagnostic criterias of them were made on the basis of clinical features, radiologic and laboratory findings and have been used decades ago. According to the development of new knowledge about etiology and pathogenesis of rheumatic diseases, the need for new criteria has been increased. In recent years, new criteria for these diseases have been developed, and they allow the early assignment of diseases and early start of therapy. In this review, the author summarizes recent advances and changes in diagnosis of rheumatoid arthritis, fibromyalgia, and spondylarthritis.
Arthritis, Rheumatoid ; Chronic Pain ; Fibromyalgia ; Rheumatic Diseases ; Spondylarthritis

OBJECTIVE: To investigate soluble Fas (sFas) protein in the sera of patients with systemic lupus erythematosus (SLE). METHODS: sfas protein was measured by sandwich ELISA METHOD: in the sera of 30 patients with SLE (mean age : 27.4+/-8.46, F:M=29:1) and 11 patients with fibromyalgia (mean age 35.8+/-11.5, F:M-11:0) as a control group. RESULTS: sfas was elevated in 6 (20%) patients of SLE and I (9%) of patients with fibromyalgia (p=0.41). sfas level was correlated with a shorter duration, lower dosage of systemic steroid and higher disease activity in patients with elevated sfas levlel compared to patients with normal serum levels of sfas. All patients with elevated sfas had been diagnosed with SLE for less than 1 month. Fifty % (6 out of 12)patients with SLE for less than I month showed elevated sfas in serum. There was no difference of in the age between patients with elevated and normal levels of sfas. CONCLUSION: These data indicate that elevated sera levels of sfas was associated with the early active phase of disease in some patients with SLE and may play a role in defective apoptosis.
Apoptosis ; Enzyme-Linked Immunosorbent Assay ; Fibromyalgia ; Humans ; Lupus Erythematosus, Systemic*